Search research articles
Contact Us
Filters
Showing results (11-20 of 29) with videos related to
Page
of 3
Sort By:
Critical Reviews in Oncology/Hematology
|
May 14, 2021
Critical review of oncology clinical trial design under non-proportional hazards
Revathi Ananthakrishnan, Stephanie Green, Alessandro Previtali, et al.
Physical Review Letters
|
March 24, 2005
Optical rheology of biological cells
Falk Wottawah, Stefan Schinkinger, Bryan Lincoln, et al.
Journal of Theoretical Biology
|
May 25, 2006
Quantifying the contribution of actin networks to the elastic strength of fibroblasts
Revathi Ananthakrishnan, Jochen Guck, Falk Wottawah, et al.
Therapeutic Innovation & Regulatory Science
|
July 1, 2026
Implementing Project Optimus in Oncology Dosage Optimization: Where are We Now?
Revathi Ananthakrishnan, Patrick Mitchell, Dong Xi, et al.
Journal of Biopharmaceutical Statistics
|
June 5, 2026
Pivotal trial design considerations for new and next generation cell and gene therapies
Patricia Anderson, Zhenzhen Xu, Evgeny Degtyarev, et al.
Journal of Cell Science
|
May 6, 2010
A mitotic kinesin-6, Pav-KLP, mediates interdependent cortical reorganization and spindle dynamics in Drosophila embryos
Patrizia Sommi, Revathi Ananthakrishnan, Dhanya K Cheerambathur, et al.
Therapeutic Innovation & Regulatory Science
|
May 4, 2024
Challenges and Lessons Learned in Autologous Chimeric Antigen Receptor T-Cell Therapy Development from a Statistical Perspective
Daniel Li, Zhenzhen Xu, Shihua Wen, et al.
International Journal of Hematology
|
January 23, 2023
Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma
Daisuke Minakata, Tadao Ishida, Kiyoshi Ando, et al.
British Journal of Haematology
|
April 23, 2016
A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy
Andre Goy, Andres Forero, Nina Wagner-Johnston, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 29, 2011
Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma
Birgit Geoerger, Mark W Kieran, Stephan Grupp, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 29) with videos related to
Sort By:
Page
of 3
Critical Reviews in Oncology/Hematology
|
May 14, 2021
Critical review of oncology clinical trial design under non-proportional hazards
Revathi Ananthakrishnan, Stephanie Green, Alessandro Previtali, et al.
Physical Review Letters
|
March 24, 2005
Optical rheology of biological cells
Falk Wottawah, Stefan Schinkinger, Bryan Lincoln, et al.
Journal of Theoretical Biology
|
May 25, 2006
Quantifying the contribution of actin networks to the elastic strength of fibroblasts
Revathi Ananthakrishnan, Jochen Guck, Falk Wottawah, et al.
Therapeutic Innovation & Regulatory Science
|
July 1, 2026
Implementing Project Optimus in Oncology Dosage Optimization: Where are We Now?
Revathi Ananthakrishnan, Patrick Mitchell, Dong Xi, et al.
Journal of Biopharmaceutical Statistics
|
June 5, 2026
Pivotal trial design considerations for new and next generation cell and gene therapies
Patricia Anderson, Zhenzhen Xu, Evgeny Degtyarev, et al.
Journal of Cell Science
|
May 6, 2010
A mitotic kinesin-6, Pav-KLP, mediates interdependent cortical reorganization and spindle dynamics in Drosophila embryos
Patrizia Sommi, Revathi Ananthakrishnan, Dhanya K Cheerambathur, et al.
Therapeutic Innovation & Regulatory Science
|
May 4, 2024
Challenges and Lessons Learned in Autologous Chimeric Antigen Receptor T-Cell Therapy Development from a Statistical Perspective
Daniel Li, Zhenzhen Xu, Shihua Wen, et al.
International Journal of Hematology
|
January 23, 2023
Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma
Daisuke Minakata, Tadao Ishida, Kiyoshi Ando, et al.
British Journal of Haematology
|
April 23, 2016
A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy
Andre Goy, Andres Forero, Nina Wagner-Johnston, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 29, 2011
Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma
Birgit Geoerger, Mark W Kieran, Stephan Grupp, et al.
Page
of 3